Last reviewed · How we verify
NCT04107103: NivoPlus
Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma
Phase 2 trial testing Combination Product: Nivolumab with Pemetrexed in SCCHN in 6 participants. Completed in 28 April 2023.
14 April 2023
Quick facts
| Lead sponsor | AHS Cancer Control Alberta |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 6 |
| Start date | 19 March 2020 |
| Primary completion | 14 April 2023 |
| Estimated completion | 28 April 2023 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Combination Product: Nivolumab with Pemetrexed — full drug profile →
Conditions studied
- SCCHN — all drugs for SCCHN →
Sponsor
AHS Cancer Control Alberta — full company profile →
Who can join
18 and older, any sex, with SCCHN. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to find out what effects the combination of Nivolumab and Pemetrexed has on you and your cancer. The safety of this combination and the effectiveness of this treatment will be studied.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
Wang H, Zhao Q, Zhang Y, Zhang Q, et al · · 2021 · cited 33× · PMID 34305889 · DOI 10.3389/fimmu.2021.652054 -
New insights into the important roles of tumor cell-intrinsic PD-1.
Zheng H, Ning Y, Zhan Y, Liu S, et al · · 2021 · cited 25× · PMID 34326692 · DOI 10.7150/ijbs.60114 -
Interplay of Immunometabolism and Epithelial-Mesenchymal Transition in the Tumor Microenvironment.
Chou MY, Yang MH. · · 2021 · cited 16× · PMID 34576042 · DOI 10.3390/ijms22189878
Verify or expand the search:
- PubMed search for NCT04107103
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for SCCHN
Currently open trials in the same condition.
- NCT06736379 — Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer · Phase 1 · recruiting
Other AHS Cancer Control Alberta trials
Trials by the same sponsor.
- NCT05128734 — Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) · Phase 2 · not yet recruiting
- NCT06860542 — Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis · Phase 2 · recruiting
- NCT05345847 — Steroid Sparing in Immune Related Hepatitis (irH) · NA · recruiting
- NCT05407987 — Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery) · Phase 3 · recruiting
- NCT05421416 — Loratadine for the Prevention of G-CSF-related Bone Pain · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04107103 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AHS Cancer Control Alberta
- Last refreshed: 14 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04107103.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing